- Update Feb. 24, 2021: Sunesis Pharmaceuticals (Nasdaq:SNSS) merged with Viracta Therapeutics (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies. The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021.
******
- Sunesis Pharma prices $20 mln offering of securities at $2.00
The co announced the pricing of underwritten public offerings of (i) 7,500,000 shares of its common stock and accompanying warrants to purchase 3,750,000 shares of its common stock and (ii) 2,500 shares of its non-voting Series D Convertible Preferred Stock and accompanying warrants to purchase 1,250,000 shares of its common stock. The public offering price of each share of common stock and accompanying warrant to purchase 0.5 shares of common stock is $2.00 and the public offering price of each share of Series D Stock, convertible into 1,000 shares of common stock, and accompanying warrant to purchase 500 shares of common stock is $2,000. The exercise price of the warrants is $3.00 per whole share of common stock. The warrants may be exercised at any time until and including October 27, 2018.
** charts before **
No comments:
Post a Comment